

GLAXOSMITHKLINE PLC
Form 6-K
April 12, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 12 April 2019

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
Chief Executive Officer
 - b) Position/status
 - c) Initial notification/
amendment Initial notification
 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7582	23
n/a (single transaction)	
- Aggregated information
- d) Aggregated volume
Price
 - e) Date of the transaction 2019-04-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Vaccines
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£15.7582 77
n/a (single transaction)
- Aggregated information
- d) Aggregated volume
Price
- e) Date of the transaction 2019-04-11
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans
b) Position/status Executive Director
c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the

re-investment of dividends
paid to shareholders on 11
April 2019, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s)
Price(s) Volume(s)
£15.7582 29
n/a (single transaction)

Aggregated information

d) Aggregated volume
Price

e) Date of the transaction 2019-04-11
f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hiron
b) Position/status SVP, Global Ethics &
Compliance
c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 11
April 2019, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s)
Price(s) Volume(s)
£15.7582 14
d) Aggregated information n/a (single transaction)

Aggregated volume
Price

- e) Date of the transaction 2019-04-11
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms S Jackson
 SVP, Global
 b) Position/status Communications and CEO
 Office
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 11
 April 2019, on shares held
 through the Company's Share
 Reward Plan.

- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.7582 71

Aggregated information

n/a (single transaction)

- d) Aggregated volume
 Price

- e) Date of the transaction 2019-04-11
 f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D Jackson
PCA of Ms S Jackson (SVP,
Global Communications and
CEO Office)
 - b) Position/status
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7582	23

 Aggregated information
n/a (single transaction)
 - d) Aggregated volume
Price
 - e) Date of the transaction 2019-04-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr L Miels
President, Global
Pharmaceuticals
 - b) Position/status
 - c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
 b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
 c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7582	4
n/a (single transaction)	

Aggregated information

- d) Aggregated volume
 Price
 e) Date of the transaction 2019-04-11
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.7582 87
 n/a (single transaction)

Aggregated information

- d) Aggregated volume
 Price
- e) Date of the transaction 2019-04-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R Simard
- b) Position/status President, Pharma Supply Chain
- c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.7582 23
- d) Aggregated information n/a (single transaction)

Aggregated volume
Price

- e) Date of the transaction 2019-04-11
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
 b) Position/status SVP, Human Resources
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.7582 87
 n/a (single transaction)

Aggregated information

d) Aggregated volume
Price

- e) Date of the transaction 2019-04-11
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status President, Global Affairs
 - c) Initial notification/
amendment Initial notification
 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.7582	50
n/a (single transaction)	
- Aggregated information
- d) Aggregated volume
Price
 - e) Date of the transaction 2019-04-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs V A Whyte
 - b) Position/status Company Secretary
 - c) Initial notification/
amendment Initial notification
- 2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019, on shares held through the Company's Share Reward Plan.
- | | | |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £15.7582 | 63 |
- n/a (single transaction)

Aggregated information

- d) Aggregated volume
 Price
- e) Date of the transaction 2019-04-11
 f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
 (Registrant)

Date: April 12, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc